Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
RANI

RANI - Rani Therapeutics Holdings, Inc. Stock Price, Fair Value and News

$0.76-0.04 (-5.00%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

23/100

RANI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

RANI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RANI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RANI Price Action

Last 7 days

-8.4%

Last 30 days

-27.6%

Last 90 days

-42.4%

Trailing 12 Months

35.7%

RANI RSI Chart

RANI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RANI Valuation

Market Cap

136.8M

Price/Earnings (Trailing)

-4.72

Price/Sales (Trailing)

43.17

EV/EBITDA

-2.69

Price/Free Cashflow

-7.97

RANI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RANI Fundamentals

RANI Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

893.02%

Rev. Growth (Qtr)

16.91%

RANI Earnings

Earnings (TTM)

-29.0M

Earnings Growth (Yr)

44.79%

Earnings Growth (Qtr)

-32.65%

RANI Profitability

EBT Margin

-2142.10%

Return on Equity

-81.51%

Return on Assets

-55.84%

Free Cashflow Yield

-12.55%

RANI Investor Care

Shares Dilution (1Y)

438.27%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20263.2M000
20251.2M1.3M1.5M1.6M
20243.0M2.5M2.1M1.0M
20232.1M3.0M3.4M3.3M
20222.3M2.0M1.6M1.2M
202101.2M2.0M2.7M
2020000462.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Rani Therapeutics Holdings, Inc.

RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
 CEO
 WEBSITEranitherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES163

Rani Therapeutics Holdings, Inc. Frequently Asked Questions

RANI is the stock ticker symbol of Rani Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Rani Therapeutics Holdings, Inc. is 136.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, RANI's PE ratio (Price to Earnings) is -4.72 and Price to Sales (PS) ratio is 43.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RANI PE ratio will change depending on the future growth rate expectations of investors.